TG Therapeutics Inc

NASDAQ:TGTX   4:00:00 PM EDT
38.84
+0.88 (+2.32%)
7:28:16 PM EDT: $38.92 +0.08 (+0.21%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)6.17B
Current PE157.50
Forward PE 47.37
2yr Forward PE 22.58
See more stats
Estimates Current Quarter
Revenue$137.13 Million
Adjusted EPS$0.19
See more estimates
10-Day MA$37.61
50-Day MA$36.22
200-Day MA$33.11
See more pivots

TG Therapeutics Inc Stock, NASDAQ:TGTX

3020 Carrington Mill Boulevard, Suite 475, Morrisville, North Carolina 27560
United States of America
Phone: +1.212.554.4484
Number of Employees: 338

Description

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.